Ionis Pharmaceuticals Files 8-K Report
Ticker: IONS · Form: 8-K · Filed: Jun 18, 2024 · CIK: 874015
Sentiment: neutral
Topics: 8-K, material-agreement, filing
Related Tickers: IONS
TL;DR
IONIS filed an 8-K on 6/18/24, likely a material agreement or financial update.
AI Summary
On June 18, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the submission of financial statements and exhibits. No specific details regarding the agreement or financial figures were provided in the excerpt.
Why It Matters
This filing indicates a significant corporate event or financial update for Ionis Pharmaceuticals, requiring disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard disclosure document without immediate negative or positive financial implications presented.
Key Numbers
- 000-19125 — SEC File Number (Identifies the company's filing history with the SEC.)
- 33-0336973 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IONIS PHARMACEUTICALS, INC. (company) — Registrant
- June 18, 2024 (date) — Date of earliest event reported
- 2855 Gazelle Court Carlsbad, CA 92010 (location) — Principal Executive Offices
- ISIS PHARMACEUTICALS INC (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement mentioned in the 8-K filing?
The provided excerpt does not specify the details of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 18, 2024.
What is the principal executive office address for Ionis Pharmaceuticals, Inc.?
The principal executive offices are located at 2855 Gazelle Court, Carlsbad, CA 92010.
What was the former name of Ionis Pharmaceuticals, Inc.?
The former name was ISIS PHARMACEUTICALS INC.
What are the main items of information disclosed in this 8-K filing?
The filing concerns the entry into a material definitive agreement and the submission of financial statements and exhibits.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-18 09:29:02
Filing Documents
- ef20031301_8k.htm (8-K) — 26KB
- ef20031301_ex99-1.htm (EX-99.1) — 16KB
- image0.jpg (GRAPHIC) — 401KB
- 0001140361-24-030447.txt ( ) — 732KB
- ions-20240618.xsd (EX-101.SCH) — 4KB
- ions-20240618_lab.xml (EX-101.LAB) — 21KB
- ions-20240618_pre.xml (EX-101.PRE) — 16KB
- ef20031301_8k_htm.xml (XML) — 4KB
01
Item 1.01 Entry into a Material Definitive Agreement. On June 18, 2024, Ionis Pharmaceuticals, Inc. (" Ionis ") issued a press release announcing it has entered into an amended and restated license agreement with Otsuka Pharmaceutical Co., Ltd. (" Otsuka ") under which Otsuka obtains exclusive rights across the Asia-Pacific region to commercialize donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Ionis will maintain primary responsibility for the development of donidalorsen, while Otsuka will be responsible for territory-specific development, regulatory filings and commercialization in the Asia-Pacific region and Europe. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated June 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: June 18, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel